MK-677 vs Wolverine Stack
Well Studied vs Well Studied
synergistic Mechanism-based · 47% MK-677 and Wolverine Stack work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
MK-677 Wolverine Stack
Weight 624.77 Da N/A
Half-life ~24 hours —
Chain — N/A
Type Non-peptide ghrelin receptor agonist Peptide blend
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Wolverine Stack
01 Complementary healing mechanisms
02 87.5% improvement in knee pain patients
03 Reduced inflammation and enhanced cell migration
04 Promotes angiogenesis and reduces scarring
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Wolverine Stack
BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose / BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
General Recovery Protocol BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week BPC-157 daily, TB-500 twice weekly
Intensive Injury Recovery BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week BPC-157 daily, TB-500 twice weekly
Maintenance/Prevention Protocol BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week BPC-157 daily, TB-500 weekly
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Wolverine Stack
Not extensively documented in human studies
Generally well-tolerated in available research
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
ANY history of cancer or suspicious growths
Active malignancy or concurrent chemotherapy
Pregnancy or breastfeeding
Research Evidence
MK-677 Wolverine Stack
Status Well Studied Well Studied
References 7 studies 6 studies
Latest July 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.